全身骨扫描在临床诊断肺癌骨转移中的作用

背景与目的:骨是肺癌最常见的转移部位之一,骨转移是肺癌患者预后较差的原因之一,较早发现骨转移,对指导临床治疗有重要意义,本研究旨在探讨99mTc-亚甲基二膦酸盐(MDP)全身骨扫描在检测肺癌患者骨转移中的作用.方法:我院2005年5月-2007年5月对400例确诊的肺癌患者进行99mTc-MDP骨显像检查,对骨转移的症状、部位、数量、病理类型、TNM分期进行回顾性分析.结果:骨痛是肺癌骨转移最常见的症状.骨转移(749处)部位以胸部骨骼为最多,共311处(41.52%),其他依次为脊柱242处(32.31%)、骨盆119处(15.89%)、四肢65处(8.68%)、颅骨12处(1.60%).多发性骨转移占80.25%(126/157).腺癌患者骨转移为48.09%(88/183),鳞癌33.33%(43/129),两者差异有显著性(P＜0.05).无其他远处转移者骨转移占30.74%(79/257);有其他远处转移者骨转移占54.55%(78/143),二者比较差异显著(P＜0.05).结论:肺癌骨转移以多发性病灶较为常见,骨转移部位以胸部、脊柱为多发,腺癌、有区域淋巴结转移及远处骨外组织转移者易发生骨转移.肺癌患者应常规进行全身骨扫描,这对疾病的分期、治疗方案的选择、预后的评价均有重要的意义.     

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases ;

Ann Oncol2003; 14: 1399–1405 The authors wish     

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.

BACKGROUND: This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate, with placebo as intravenous (i.v.) therapy in metastatic bone disease due to breast cancer. PATIENTS AND METHODS: A total of 466 patients were randomised to receive placebo (n = 158), or 2 mg (n = 154) or 6 mg (n = 154) ibandronate every 3-4 weeks for up to 2 years. The primary efficacy parameter was the number of 12-week periods with new bone complications, expressed as the skeletal morbidity period rate (SMPR). Bone pain, analgesic use and safety were evaluated monthly. Results SMPR was lower in both ibandronate groups compared with the placebo group; the difference was statistically significant for the ibandronate 6 mg group (P = 0.004 versus placebo). Consistent with the SMPR, ibandronate 6 mg significantly reduced the number of new bone events (by 38%) and increased time to first new bone event. Patients on ibandronate 6 mg also experienced decreased bone pain scores and analgesic use. Treatment with ibandronate was well tolerated. CONCLUSIONS: These results indicate that 6 mg i.v. ibandronate is effective and safe in the treatment of bone metastases from breast cancer.     

肺癌骨转移核素显像分析

目的探讨肺癌骨转移患者骨显像的特点及规律。方法136例肺癌患者做全身骨核素显像。结果136例肺癌患者中有87例骨显像异常,结合临床及X线诊断为骨转移,骨转移的发生率为63.97%。其中左肺癌的阳性率为58.33%,右肺癌的阳性率为73.47%。肺腺癌的阳性率72.41%,肺鳞癌的阳性率为43.48%,腺癌较鳞癌容易发生骨转移(P<0.05)。87例骨转移患者中81例为多发病灶(占93.1%),6例为单发病灶(占6.9%),每例患者的平均病灶数为6.39个。骨转移的部位以胸部为多见,其余依次为脊柱、骨盆、肢体和颅骨。伴有区域淋巴结及远处其它器官转移的患者出现骨显像异常的可能显著增多(P<0.05),骨转移是否发生与肿瘤原发病灶范围之间的关系未能得到统计学证实。结论肺癌骨转移发生率很高,骨转移的发生有一定的规律及特点,核素全身骨显像对于临床诊断分期及治疗决策有一定的意义。     

伊班膦酸钠联合化疗对肺癌骨转移的临床疗效

目的观察伊班膦酸钠(艾本)联合化疗对肺癌骨转移的止痛效果和不良反应。方法将67例患者分为A、B两组,A组为伊班膦酸钠联合化疗组,B组为单用伊班膦酸钠组。结果A、B两组止痛有效率分别为79.4%和72.7%,差异无显著性(P>0.05)。结论伊班膦酸钠可与化疗联合应用治疗肺癌骨转移性疼痛,且安全有效。     

A case of lung resection after chemotherapy due to lung metastases derived from esophageal cancer resection

We report a rare case of esophageal cancer resection in which lung metastases was resected after chemotherapy with paclitaxel. A 59-year-old man with epigastralgia as a chief concern was referred to our hospital and was diagnosed with esophageal cancer by gastrointestinal fiber. In June 2007, the cancer was resected and followed by 3 courses of weekly chemotherapy with paclitaxel. In January 2009, chest computed tomography showed lung nodules (Rt-S1 and Rt-S5), and positron emission tomography (PET) showed uptake (Rt-S1); a final diagnosis of multiple lung metastases was made. Thereafter, the patient underwent 8 courses of weekly chemotherapy with paclitaxel. In December 2009, the growing Rt-S1 nodule was detected but no other lesion. The patient underwent a resection of lung metastases followed by 5 courses of weekly chemotherapy with paclitaxel. As of June 2011, the patient was alive and disease free. In conclusion, the resection of solitary lung metastases derived from esophageal cancer should be considered because it may improve survival.